Patient-derived organoids predict clinical response: a patient in the lab

A large fraction of the colorectal cancer patients diagnosed with de novo metastatic disease (mCRC) do not benefit from current standard of care and experience substantial side effects. Therefore, there is an urgent need for advanced preclinical models to predict clinical response.

Patient-derived organoids (PDO) can be developed from healthy as well as diseased tissue, including cancer lesions, and therefore faithfully recapitulate patient disease in vitro, and can be propagated for drug testing in a matter of weeks.

Download our poster to discover:

• The establishment and characterization of a biobank of mCRC organoids
• Validation data on the predictive value of PDOs in the stratification of mCRC patients
• Current efforts on the establishment of an automated system for selecting, picking, and placing organoids for accelerating drug screening in organoids